A 32-year-old Rh-negative woman at 16 weeks of gestation is found to have an indirect Coombs test (ICT) titre of 1:8 on routine antenatal screening. Her partner is Rh-positive. She has no history of prior transfusion or sensitising events. Which investigation is most appropriate to confirm the specificity of the antibody and guide further management?

Explanation

## Antibody Identification in Rh Isoimmunisation ### Clinical Context This patient has a **positive ICT** (1:8 dilution) detected at 16 weeks in an Rh-negative woman with an Rh-positive partner. The ICT confirms the presence of **irregular antibodies** (alloantibodies), but does not identify **which antibody** is present. Identifying the specific antibody is critical because: - **Anti-D** is the most common and most clinically significant in Rh disease. - Other antibodies (anti-C, anti-E, anti-Kell) may have different clinical implications and management strategies. - The specificity determines risk stratification and investigation frequency. ### Why Antibody Identification Panel is Correct **Key Point:** Antibody identification (panel) testing is the **gold standard** for determining the specific alloantibody present when ICT is positive. **Mechanism:** - Panel testing uses a standardized set of red blood cells (RBCs) with known antigen profiles. - The maternal serum is tested against each panel cell at multiple temperatures (room temperature, 37°C, and with enhancement media like albumin or LISS). - The pattern of agglutination identifies which antigen the antibody is directed against. **Clinical Significance:** - **Anti-D:** Most common (95% of alloimmunised pregnancies); causes severe HDN; requires close monitoring and possible IUT. - **Anti-C, Anti-E:** Less common; variable severity; may not require IUT even if present. - **Anti-Kell:** Rare; can cause severe anaemia; management similar to anti-D. **High-Yield:** In NEET PG, remember that **antibody identification is mandatory** when ICT is positive in the first trimester or early second trimester. It guides the frequency of monitoring (anti-D requires monthly or bi-weekly ICT; other antibodies may require less frequent monitoring). ### Comparison of Antibody Detection and Identification Methods | Test | Purpose | Timing | Clinical Use | |---|---|---|---| | **Indirect Coombs Test (ICT)** | Detect presence of irregular antibodies | Routine screening, serial monitoring | Confirms alloimmunisation; titre correlates with risk | | **Antibody Identification Panel** | Identify specific antibody (anti-D, anti-C, etc.) | After positive ICT | Determines severity risk and monitoring frequency | | **Repeat ICT (saline/albumin)** | Enhance detection sensitivity | Rarely used now | Outdated; panel testing is more specific | | **Direct Coombs Test (DAT)** | Detect IgG on fetal RBCs | Fetal blood via cordocentesis | Confirms fetal involvement; not first-line | | **Kleihauer-Betke** | Quantify FMH | Postnatal or after sensitising event | Dosing RhIG; not for antibody identification | **Clinical Pearl:** Once antibody identification confirms anti-D, the next step is **serial ICT monitoring** (monthly until 24 weeks, then bi-weekly) and **MCA-PSV Doppler** (from 18 weeks) to assess fetal anaemia severity. If ICT titre rises to ≥1:16 or MCA-PSV >1.5 MoM, cordocentesis and intrauterine transfusion are considered. **Warning:** Do not confuse **antibody detection** (ICT) with **antibody identification** (panel). ICT tells you an antibody is present; panel testing tells you **which one**. Both are needed for complete assessment. ### Why Repeat ICT with Different Temperatures is Outdated Historically, repeating ICT at different temperatures and with enhancement media was used to optimise detection. Modern practice uses **antibody identification panels**, which are more specific and standardised.